Patents by Inventor Philip Anthony Morganelli

Philip Anthony Morganelli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170260204
    Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, W, Y1, Y2, Z1, and Z4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: May 18, 2017
    Publication date: September 14, 2017
    Inventors: Elizabeth M. Bacon, Zhenhong R. Cai, Xiaowu Chen, Jeromy J. Cottell, Manoj C. Desai, Mingzhe Ji, Haolun Jin, Scott E. Lazerwith, Michael R. Mish, Philip Anthony Morganelli, Hyung-Jung Pyun, James G. Taylor, Teresa Alejandra Trejo Martin
  • Patent number: 9732092
    Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, W, Y1, Y2, Z1, and Z4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: August 15, 2017
    Assignee: Gilead Sciences, Inc.
    Inventors: Haolun Jin, Scott E. Lazerwith, Hyung-Jung Pyun, Elizabeth M. Bacon, Philip Anthony Morganelli, Mingzhe Ji
  • Publication number: 20170119764
    Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (Ia): including stereoisomers and pharmaceutically acceptable salts thereof, wherein A?, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: November 11, 2016
    Publication date: May 4, 2017
    Inventors: Elizabeth M. Bacon, Zhenhong R. Cai, Jeromy J. Cottell, Mingzhe Ji, Haolun Jin, Scott E. Lazerwith, Philip Anthony Morganelli, Hyung-Jung Pyun
  • Publication number: 20170057976
    Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, W, Y1, Y2, Z1, and Z4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: November 11, 2016
    Publication date: March 2, 2017
    Inventors: Haolun Jin, Scott E. Lazerwith, Hyung-Jung Pyun, Manoj C. Desai, Teresa Alejandra Trejo, Elizabeth Bacon, Jeromy J. Cottell, Zhenhong R. Cai, Philip Anthony Morganelli, Mingzhe Ji, James G. Taylor, Xiaowu Chen, Michael R. Mish
  • Patent number: 9522912
    Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (Ia): including stereoisomers and pharmaceutically acceptable salts thereof, wherein A?, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: December 20, 2016
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Elizabeth M. Bacon, Zhenhong R. Cai, Jeromy J. Cottell, Mingzhe Ji, Haolun Jin, Scott E. Lazerwith, Philip Anthony Morganelli, Hyung-jung Pyun
  • Publication number: 20160176870
    Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (Ia): including stereoisomers and pharmaceutically acceptable salts thereof, wherein A?, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: December 21, 2015
    Publication date: June 23, 2016
    Inventors: Elizabeth M. Bacon, Zhenhong R. Cai, Jeromy J. Cottell, Mingzhe Ji, Haolun Jin, Scott E. Lazerwith, Philip Anthony Morganelli, Hyung-jung Pyun
  • Publication number: 20160176885
    Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, W, Y1, Y2, Z1, and Z4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: July 31, 2015
    Publication date: June 23, 2016
    Inventors: Haolun Jin, Scott E. Lazerwith, Hyung-Jung Pyun, Manoj C. Desai, Teresa Alejandra Trejo Martin, Elizabeth Bacon, Jeromy J. Cottell, Zhenhong R. Cai, Philip Anthony Morganelli, Mingzhe Ji, James G. Taylor, Xiaowu Chen, Michael R. Mish
  • Patent number: 9321753
    Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: April 26, 2016
    Assignee: Gilead Sciences, Inc.
    Inventors: Eda Canales, Michael O'Neil Hanrahan Clarke, Scott E. Lazerwith, Willard Lew, Philip Anthony Morganelli, William J. Watkins
  • Publication number: 20140221356
    Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, W, Y1, Y2, Z1, and Z4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: December 19, 2013
    Publication date: August 7, 2014
    Inventors: Haolun JIN, Scott E. LAZERWITH, Teresa Alejandra TREJO MARTIN, Elizabeth M. BACON, Jeromy J. COTTELL, Zhenhong R. CAI, Hyung-Jung PYUN, Philip Anthony MORGANELLI, Mingzhe JI, James G. TAYLOR, Xiaowu CHEN, Michael R. MISH, Manoj C. DESAI
  • Publication number: 20140030223
    Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.
    Type: Application
    Filed: September 25, 2013
    Publication date: January 30, 2014
    Applicant: Gilead Sciences, Inc.
    Inventors: Eda Canales, Lee S. Chong, Michael O'Neil Hanrahan Clarke, Edward Doerffler, Scott E. Lazerwith, Willard Lew, Qi Liu, Michael Martzman, Philip Anthony Morganelli, William J. Watkins, Hong Ye
  • Publication number: 20130323203
    Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.
    Type: Application
    Filed: August 2, 2013
    Publication date: December 5, 2013
    Applicant: Gilead Sciences, Inc.
    Inventors: Eda Canales, Lee S. Chong, Michael O'Neil Hanrahan Clarke, Edward Doerffler, Scott E. Lazerwith, Willard Lew, Michael Mertzman Belmont, Philip Anthony Morganelli, William J. Watkins
  • Publication number: 20130315861
    Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.
    Type: Application
    Filed: July 11, 2013
    Publication date: November 28, 2013
    Inventors: Eda Canales, Michael O'Neil Hanrahan Clarke, Scott E. Lazerwith, Willard Lew, Philip Anthony Morganelli, William J. Watkins
  • Patent number: 8513298
    Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: August 20, 2013
    Assignee: Gilead Sciences, Inc.
    Inventors: Eda Canales, Michael O'Neil Hanrahan Clarke, Scott E. Lazerwith, Willard Lew, Philip Anthony Morganelli, William J. Watkins
  • Publication number: 20110178129
    Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.
    Type: Application
    Filed: January 14, 2011
    Publication date: July 21, 2011
    Applicant: Gilead Sciences, Inc.
    Inventors: Eda Canales, Michael O' Neil Hanrahan Clarke, Scott E. Lazerwith, Willard Lew, Philip Anthony Morganelli, William J. Watkins